Eden Wells, Novartis chief insights and decision science officer, at the Financial Times' US Pharma and Biotech Summit, held in partnership with Endpoints News (Sarah Merians Photography for Endpoints News)

May 16, 2024 03:18 PM EDT

Health Tech

Pharma is rethinking how it interacts with patients after Eli Lilly ripped up the playbook

Shelby Livingston

Senior health tech reporter

(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.)

More pharma companies …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pharma is rethinking how it interacts with patients after Eli Lilly ripped up the playbook

Shelby Livingston

Senior health tech reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Exclusive: Influential Democrat will oppose Biosecure Act ahead of House vote

Astellas CEO talks future beyond Xtandi as Japanese drugmaker puts roots in Boston

BridgeBio sticks to script for ATTR-CM as Alnylam cleans up ‘typo’ snafu

Roche's Spark loses CEO to RNA upstart; Ex-Elevation Oncology chief takes over at Affimed

Lilly inks obesity deal with seed-stage RNA startup as its genetic medicines effort enters the spotlight

How to secure full enrollment and a 30x ROI: A conversation with the CEO of the boutique enrollment agency doing just ...

Phar­ma is re­think­ing how it in­ter­acts with pa­tients af­ter Eli Lil­ly ripped up the play­book

Senior health tech reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Pharma is rethinking how it interacts with patients after Eli Lilly ripped up the playbook